Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Global Cross-Pharmaceutical Clinical Trial Investigator Databank Established

Published: Friday, November 16, 2012
Last Updated: Friday, November 16, 2012
Bookmark and Share
Lilly and Merck are first to join Janssen in this pre-competitive initiative to increase efficiencies in clinical trials.

Janssen Research & Development, LLC (Janssen R&D) today announced the establishment of a global cross-pharmaceutical Investigator Databank designed to improve efficiencies of industry-sponsored clinical trials. Merck and Eli Lilly and Company are the first two companies to join Janssen in this effort.

The new Investigator Databank, established as part of this novel industry collaboration, will serve as a one-stop repository where key information about clinical trial sites, such as infrastructure and Good Clinical Practice (GCP) training records, is housed.   This will allow participating pharmaceutical companies to reduce  time-consuming and sometimes redundant administrative work involved in identifying appropriate clinical trial sites.

At the outset of every clinical trial, pharmaceutical companies initiate clinical trial site selection, prequalification and GCP training, which can be paperwork-heavy and time-consuming for trial sponsors and investigators alike.  By housing critical information about investigators and trial sites in one place, the databank will reduce time, cost and duplicative efforts, making it easier for companies to identify appropriate trial sites and investigators for future clinical trials. Investigator sites that have opted-in to data sharing will have their relevant information accessible to pharmaceutical companies participating in the collaboration. This databank will not include any patient data.

“The current clinical trial environment is inefficient, costly and unsustainable.  The  Investigator Databank can help expedite the process to achieve our most important goal – to deliver high-quality, effective novel medicines to the patients who  are waiting for them,” said Andreas Koester, MD, PhD, Head, Clinical Trial Innovation/External Alliances, Janssen Research & Development.  “We are enthusiastic about working with other industry leaders to collectively apply our expertise, capabilities and shared passion for advancing science and improving lives.”

Earlier this year, Janssen joined nine other companies to launch TransCelerate BioPharma Inc. ("TransCelerate"), the largest initiative of its kind, which aims to identify and overcome common drug development challenges in order to improve the quality of clinical studies and to bring new medicines to patients faster.  The initiative identified the centralization of site prequalification and training as one of five key projects, and the Janssen-led Investigator Databank project will serve as a foundation for the TransCelerate initiative.

“Industry collaboration, including pre-competitive data sharing, is critical to ensuring continued progress to improve industry-wide clinical trial practices,” said newly appointed CEO of TransCelerate BioPharma, Garry Neil, MD, Partner at Apple Tree Partners and formerly Corporate Vice President, Science & Technology, Johnson & Johnson. “This work is aligned with TransCelerate’s initial focus on clinical study execution and we encourage participation from our founding TransCelerate companies to solve industry-wide challenges in a collaborative environment.”

Member companies of TransCelerate who wish to join the Investigator Databank will automatically qualify for participation. It is anticipated that the Investigator Databank will be operational by the end of the year and incorporated into one of the priority projects within TransCelerate by mid-2013.

The Investigator Databank will be hosted by DrugDev.org, an independent, third party with expertise in clinical trial information technology and investigator community management.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

J&JPRD Joins the Simcyp Consortium and Licenses the Simcyp Simulator
J&JPRD is now providing access to the Simcyp Population-based ADME Simulator and Paediatric module to its global network of research & development teams.
Wednesday, May 28, 2008
Scientific News
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Cancer Cells Kill Off Healthy Neighbours
Cancer cells create space to grow by killing off surrounding healthy cells, according to UK researchers working with fruit flies.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Bile Acid Supports Production of Blood Stem Cells
A research group at Lund University has been able to show that bile acid is transferred from the mother to the foetus via the placenta to enable the foetus to produce blood stem cells.
Chemical Used to Replace BPA is Potentially Toxic
This study is the first to examine the effects of BPA and BPS on brain cells and genes that control the growth and function of organs involved in reproduction.
A Better Model for Parkinson's
Scientists at EPFL solve a longstanding problem with modeling Parkinson’s disease in animals. Using newfound insights, they improve both cell and animal models for the disease, which can propel research and drug development.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Toxicity Testing With Cultured Liver Cells
Microreactor replaces animal testing.
Neural Networks Adapt to the Presence of a Toxic HIV Protein
HIV-associated neurocognitive disorders (HAND) afflict approximately half of HIV infected patients.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!